We welcome conversations with strategic pharma, specialty wound-care companies, foundations, family offices, and accredited investors who share our conviction that advanced healing should be universal.
Novel small-molecule MOA with no approved therapeutic in this target class. Category-defining IP runway.
Comprehensive preclinical package complete: efficacy, tox, ICH stability, ADME — all positive.
Shelf-stable, ambient-temperature storage — uniquely suited to real-world deployment.
$18B+ global wound-care market at 6.2% CAGR. Significant unmet need across DFU, VLU, pressure, surgical.
Pre-IND meeting · IND filing · Phase I read-out — three near-term value events within 24 months.
Designed for out-licensing or co-development with major pharma / specialty wound-care companies post Phase I.
Co-development, regional rights, and out-licensing conversations with global pharma and specialty wound-care companies — particularly those with established commercial infrastructure in DFU and post-acute care.
Foundations, family offices, and impact-focused investors who care about both category-defining returns and the ability to reach patients in markets biologics can’t serve.
Defense departments, BARDA-type stakeholders, and global-health agencies interested in shelf-stable therapeutics for trauma, disaster and rural deployment.
Qualified partners and accredited investors receive a full diligence package on request.
This page is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. It contains forward-looking statements that involve risks and uncertainties; actual results may differ materially. Materials are intended solely for accredited investors and qualified institutional buyers. Recipients should conduct their own due diligence and consult with their financial, legal, and regulatory advisors before making any decision.
If you’d like to learn more about ZegeneX, we’d be delighted to share our data, our team, and the path forward in confidence.
A preclinical-stage biopharmaceutical company developing first-in-class, shelf-stable wound healing therapeutics — making advanced care accessible everywhere.
